Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)
Publication
, Conference
Mutch, D; Orlando, M; Teneriello, T; Gordon, A; McMeekin, S; Goss, T; Scribner, D; Naumann, R; Secord, AA; Wang, Y
Published in: Ejc Supplements
October 1, 2005
Duke Scholars
Published In
Ejc Supplements
ISSN
1359-6349
Publication Date
October 1, 2005
Volume
3
Issue
2
Start / End Page
262 / 262
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Mutch, D., Orlando, M., Teneriello, T., Gordon, A., McMeekin, S., Goss, T., … Wang, Y. (2005). Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct). In Ejc Supplements (Vol. 3, pp. 262–262). PERGAMON-ELSEVIER SCIENCE LTD.
Mutch, D., M. Orlando, T. Teneriello, A. Gordon, S. McMeekin, T. Goss, D. Scribner, R. Naumann, A Alvarez Secord, and Y. Wang. “Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct).” In Ejc Supplements, 3:262–262. PERGAMON-ELSEVIER SCIENCE LTD, 2005.
Mutch D, Orlando M, Teneriello T, Gordon A, McMeekin S, Goss T, et al. Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct). In: Ejc Supplements. PERGAMON-ELSEVIER SCIENCE LTD; 2005. p. 262–262.
Mutch, D., et al. “Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct).” Ejc Supplements, vol. 3, no. 2, PERGAMON-ELSEVIER SCIENCE LTD, 2005, pp. 262–262.
Mutch D, Orlando M, Teneriello T, Gordon A, McMeekin S, Goss T, Scribner D, Naumann R, Secord AA, Wang Y. Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct). Ejc Supplements. PERGAMON-ELSEVIER SCIENCE LTD; 2005. p. 262–262.
Published In
Ejc Supplements
ISSN
1359-6349
Publication Date
October 1, 2005
Volume
3
Issue
2
Start / End Page
262 / 262
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
Related Subject Headings
- Oncology & Carcinogenesis